Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager
1. Zymeworks discontinues ZW171 due to unfavorable trial results. 2. Complete dose escalation confirmed dose-limiting toxicities related to mesothelin. 3. Ongoing efforts focus on advancing ZYME's broader product pipeline. 4. Zanidatamab receives multiple regulatory approvals, increasing its commercial potential. 5. Future studies for ZW191 and ZW251 are expected to progress.